NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VCEL stock has increased by 25.6% and is now trading at $15.17.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Vericel.

Vericel Corp (NASDAQ:VCEL) posted its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.03. The biotechnology company earned $20 million during the quarter, compared to analyst estimates of $19.31 million. Vericel had a positive return on equity of 5.87% and a negative net margin of 9.39%. The business's revenue was down 23.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.05) EPS.
View Vericel's earnings history.

Vericel updated its second quarter 2020 Pre-Market earnings guidance on Thursday, July, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $15.79 million.

5 equities research analysts have issued 1-year price targets for Vericel's stock. Their forecasts range from $21.00 to $32.00. On average, they anticipate Vericel's share price to reach $24.25 in the next year. This suggests a possible upside of 59.9% from the stock's current price.
View analysts' price targets for Vericel.

News headlines about VCEL stock have been trending very positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vericel earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term.
View the latest news about Vericel.

Some companies that are related to Vericel include Fate Therapeutics (FATE), Immunovant (IMVT), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), Sangamo Therapeutics (SGMO), Legend Biotech (PCVX), Bill.com (RVMD), Adverum Biotechnologies (ADVM), NanoString Technologies (NSTG), Forma Therapeutics (FMTX), Regenxbio (RGNX), Coherus Biosciences (CHRS), Cortexyme (CRTX) and Beam Therapeutics (BEAM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Fort Washington Investment Advisors Inc. OH (1.55%), GW&K Investment Management LLC (1.47%), Summit Creek Advisors LLC (1.05%), Mutual of America Capital Management LLC (0.87%), Cadence Capital Management LLC (0.28%) and WINTON GROUP Ltd (0.26%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman.
View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Emerald Advisers LLC, GW&K Investment Management LLC, Falcon Point Capital LLC, Alps Advisors Inc., Fort Washington Investment Advisors Inc. OH, Mesirow Financial Investment Management Inc., and SG Americas Securities LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, and Michael Halpin.
View insider buying and selling activity for Vericel.

VCEL stock was acquired by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Cadence Capital Management LLC, WINTON GROUP Ltd, Conestoga Capital Advisors LLC, Mutual of America Capital Management LLC, Dupont Capital Management Corp, Raymond James Financial Services Advisors Inc., and Russell Investments Group Ltd..
View insider buying and selling activity for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $15.17.

Vericel has a market capitalization of $684.33 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]